How to assess response to immune therapy

 

Authors

  • Judith Michels Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France.
  • Emilie Lanoy Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, F-94085, France.
  • Caroline Caramella Département d’Imagerie, Gustave Roussy Cancer Campus, Villejuif, France.
  • Christian Marth AGO–Austria and Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.

DOI:

https://doi.org/10.19156/cbn.2016.0029

Keywords:

microbiota, PD-L1, pseudo-progression, RECIST, local and peripheral immune response

Abstract

Immunotherapy is already a mainstay in treating melanoma, lung cancer and renal cancer and shows compelling promise in many different tumors. However, responses to immunotherapy may be present despite apparent initial progression of the tumor. This underlines the importance of defining accurate tumor assessments and response criteria for immunotherapy. The RECIST criteria have therefore been modified to adhere to requirements of immunotherapy. In line with that, this review will focus on the current imaging tools, the statistical evaluations in clinical trials and the biological analysis of the tumor microenvironment that will in the future effectively guide treatment decisions in everyday clinical practice.

Downloads

Published

2016-12-15

How to Cite

1.
Michels J, Lanoy E, Caramella C, Marth C. How to assess response to immune therapy:  . CBN [Internet]. 2016 Dec. 15 [cited 2024 Nov. 24];4(3):47-51. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/225

Issue

Section

Methodological corner